Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.5.0.2
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 5 Months Ended 9 Months Ended 70 Months Ended
May 31, 2016
Sep. 30, 2015
Jan. 31, 2015
Dec. 31, 2010
Sep. 30, 2016
Sep. 30, 2015
Mar. 31, 2015
Sep. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Dec. 31, 2015
Jul. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Revenue from transfer of intellectual property and other         $ 18,441,000 $ 18,350,000     $ 105,338,000 $ 48,552,000      
Deferred revenue         180,400,000     $ 180,400,000 180,400,000   $ 180,400,000 $ 232,900,000  
Payment of grant repayment obligation             $ 25,900,000            
Grant repayment         0 0     0 25,889,000      
VFMCRP                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Milestone revenue recognized               0          
VFMCRP | Development and License Agreement                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
License revenue, initial payment $ 50,000,000               50,000,000        
Royalty revenue, obligation period after first product sale 10 years                        
VFMCRP | Regulatory Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received $ 37,000,000                        
VFMCRP | Launch and Sales-based Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received 195,000,000                        
VFMCRP | Exclusive Option                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received $ 555,000,000                        
Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received     $ 275,000,000                    
Non-refundable and non-creditable upfront payment     295,000,000.0                    
Revenue from transfer of intellectual property and other         17,700,000 $ 17,700,000     53,000,000 47,800,000      
Deferred revenue         176,500,000     176,500,000 176,500,000   176,500,000    
Tesaro                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received       $ 30,000,000                  
Milestone revenue recognized                 0 $ 0      
Upfront payment under license agreements       6,000,000.0                  
Milestone payment received                     20,000,000    
Additional milestone payment       $ 85,000,000                  
Period from first commercial sale       12 years                  
Merck | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received   $ 5,000,000                      
Non-refundable and non-creditable upfront payment   23,000,000                      
Milestone payment received                 13,900,000        
Amount payable each year   $ 5,000,000                      
Period for yearly payment   4 years                      
Intangible assets, estimated useful lives   13 years                      
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Deferred revenue         70,600,000     70,600,000 70,600,000   70,600,000    
Accrued Expenses | Merck | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Milestone payment received                 4,800,000        
Other Noncurrent Liabilities | Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Deferred revenue         $ 105,900,000     $ 105,900,000 105,900,000   $ 105,900,000    
Other Noncurrent Liabilities | Merck | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Milestone payment received                 $ 9,100,000        
Minimum                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Intangible assets, estimated useful lives                 3 years        
Minimum | Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Each milestone payment     20,000,000                    
Maximum                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Intangible assets, estimated useful lives                 20 years        
Maximum | Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Each milestone payment     $ 90,000,000                    
Pharmsynthez                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Ownership percentage         17.00%     17.00% 17.00%   17.00%    
Rxi Pharmaceuticals Corporation                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Maximum milestone payments to be received             $ 50,000,000.0            
Pharmsynthez Note Receivable | Notes | Pharmsynthez                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Debt face amount                         $ 3,000,000.0